Skip to main content

Table 5 District reported coverage and validated survey coverage data from national post-MDA drug coverage survey

From: A mixed methods approach to evaluating community drug distributor performance in the control of neglected tropical diseases

District

Drug packages

Coverage

  

Reported

Survey

  

Treated

Therapeutic coverage (%)a

Programme coverage (%)b

Median (%)

n

95 % CI

Kamuli

ZIT

396,700

61 

63 

36.73c

1078

33.85–39.61

 

IVM + ALB

508,573

78 

97

52.71c

1089

49.73–55.67

 

PZQ

29,470

75 

94 

57.39c

1089

54.45–60.33

Mayuge

ZIT

182,763

44

46

13.07c

1094

11.07–15.07

 

PZQ + ALB

37,666

28

35

36.42

1102

32.43–40.42

Yumbe

IVM + ALB

295,179

74

93

72.76

984

69.97–75.55

 

PZQ

278,670

70

88

77.16c

972

74.51–79.80

Pallisa

IVM + ALB

386,859

92

96

62.59c

1096

59.72–65.46

  1. aTherapeutic coverage is the (Number of individuals ingesting the PCT drugs for a specific disease in an endemic country/district etc./Total number of individuals in the country/district etc., all at risk of infection) × 100 [44]
  2. bProgramme coverage is the (Number of individuals in the target population ingesting the PCT drugs in [x] endemic area/All the eligible individuals targeted for treatment in the [x] endemic area) × 100 [44]
  3. creported at-risk or eligible coverage lies out-with the validated survey coverage 95 % confidence interval